IMVT (Immunovant) Margin of Safety % (DCF Dividends Based) : N/A (As of Mar. 04, 2025)

View and export this data going back to 2019. Start your Free Trial

What is Immunovant Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Immunovant's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Immunovant's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Immunovant's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunovant's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunovant's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Immunovant's Margin of Safety % (DCF Dividends Based) falls into.

Immunovant Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Immunovant's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunovant Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunovant Inc (NAS:IMVT) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

320 West 37th Street, 6th Floor, New York, NY, USA, 10018

Website

https://www.immunovant.com

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Executives

Jay S Stout	officer: Chief Technology Officer	C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
William L. Macias	officer: Chief Medical Officer	C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Eva Renee Barnett	officer: Chief Financial Officer	C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Peter Salzmann	director, officer: Chief Executive Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Douglas J. Hughes	director	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Mark S. Levine	officer: Chief Legal Officer	1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Julia G. Butchko	officer: Chief Dev. & Tech. Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Andrew J. Fromkin	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
George V Migausky	director	C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Frank Torti	director	2855 SAND HILL ROAD, MENLO PARK CA 94025
Rita Jain	officer: Chief Medical Officer	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Michael James Elliott	officer: Chief Scientific Officer	320 WEST 37TH STREET, NEW YORK NY 10018
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018